Oren Livnat
Stock Analyst at HC Wainwright & Co.
(3.64)
# 718
Out of 5,182 analysts
124
Total ratings
54.62%
Success rate
23.14%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Oren Livnat
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PCRX Pacira BioSciences | Maintains: Buy | $48 → $65 | $25.41 | +155.80% | 20 | Apr 8, 2025 | |
| VRCA Verrica Pharmaceuticals | Reiterates: Neutral | n/a | $6.53 | - | 12 | Apr 8, 2025 | |
| COLL Collegium Pharmaceutical | Reiterates: Buy | $50 | $32.81 | +52.39% | 10 | Mar 24, 2025 | |
| TRVI Trevi Therapeutics | Reiterates: Buy | $13 | $13.84 | -9.68% | 7 | Mar 19, 2025 | |
| ANIP ANI Pharmaceuticals | Reiterates: Buy | $94 | $78.50 | +19.75% | 13 | Mar 17, 2025 | |
| ZVRA Zevra Therapeutics | Reiterates: Buy | $20 | $9.90 | +102.02% | 9 | Mar 13, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $200 → $217 | $203.98 | +6.38% | 17 | Mar 10, 2025 | |
| XERS Xeris Biopharma Holdings | Reiterates: Buy | $6.6 → $8 | $6.09 | +31.36% | 11 | Mar 7, 2025 | |
| TARS Tarsus Pharmaceuticals | Reiterates: Buy | $73 | $62.09 | +17.57% | 9 | Feb 26, 2025 | |
| GRCE Grace Therapeutics | Reiterates: Buy | $12 | $2.10 | +471.43% | 1 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7.5 | $2.79 | +168.82% | 6 | Jan 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $8 | $0.99 | +711.52% | 2 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $60 | $2.31 | +2,475.76% | 5 | Aug 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $252 → $198 | $0.64 | +30,842.33% | 2 | May 7, 2021 |
Pacira BioSciences
Apr 8, 2025
Maintains: Buy
Price Target: $48 → $65
Current: $25.41
Upside: +155.80%
Verrica Pharmaceuticals
Apr 8, 2025
Reiterates: Neutral
Price Target: n/a
Current: $6.53
Upside: -
Collegium Pharmaceutical
Mar 24, 2025
Reiterates: Buy
Price Target: $50
Current: $32.81
Upside: +52.39%
Trevi Therapeutics
Mar 19, 2025
Reiterates: Buy
Price Target: $13
Current: $13.84
Upside: -9.68%
ANI Pharmaceuticals
Mar 17, 2025
Reiterates: Buy
Price Target: $94
Current: $78.50
Upside: +19.75%
Zevra Therapeutics
Mar 13, 2025
Reiterates: Buy
Price Target: $20
Current: $9.90
Upside: +102.02%
Jazz Pharmaceuticals
Mar 10, 2025
Maintains: Buy
Price Target: $200 → $217
Current: $203.98
Upside: +6.38%
Xeris Biopharma Holdings
Mar 7, 2025
Reiterates: Buy
Price Target: $6.6 → $8
Current: $6.09
Upside: +31.36%
Tarsus Pharmaceuticals
Feb 26, 2025
Reiterates: Buy
Price Target: $73
Current: $62.09
Upside: +17.57%
Grace Therapeutics
Feb 18, 2025
Reiterates: Buy
Price Target: $12
Current: $2.10
Upside: +471.43%
Jan 4, 2024
Reiterates: Buy
Price Target: $7.5
Current: $2.79
Upside: +168.82%
May 13, 2022
Maintains: Buy
Price Target: $14 → $8
Current: $0.99
Upside: +711.52%
Aug 26, 2021
Maintains: Buy
Price Target: $43 → $60
Current: $2.31
Upside: +2,475.76%
May 7, 2021
Maintains: Buy
Price Target: $252 → $198
Current: $0.64
Upside: +30,842.33%